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 Planarians in pharmacology: 
parthenolide is a specific behavioral antagonist of cocaine
in the planarian Girardia tigrina
ONÉ R. PAGÁN*,1, DEBRA BAKER1, SEAN DEATS2, ERICA MONTGOMERY1,
MATTHEW TENAGLIA1, CLINITA RANDOLPH1, DHARINI KOTTURU1, CHRISTOPHER TALLARIDA3,
DANIEL BACH1, GALIA WILK1, SCOTT RAWLS4 and ROBERT B. RAFFA3
1Department of Biology, West Chester University, West Chester, 2Department of Psychology, West Chester 
University, West Chester, 3Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 
Philadelphia and 4Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA
ABSTRACT  Planarians are traditional animal models in developmental and regeneration biology. 
Recently, these organisms are arising as vertebrate-relevant animal models in neuropharmacol-
ogy. Using an adaptation of published behavioral protocols, we have described the alleviation of 
cocaine-induced planarian seizure-like movements (pSLM) by a naturally-occurring sesquiterpene 
lactone, parthenolide. Interestingly, parthenolide does not prevent the expression of pSLM induced 
by amphetamines; in vertebrates, amphetamines interact with the same protein target as cocaine. 
Parthenolide is also unable to prevent pSLM elicited by the cholinergic compounds nicotine and 
cytisine or by the glutamatergic agents L- or D- glutamic acid or NMDA. Thus, we conclude that 
parthenolide is a specific anti-cocaine agent in this experimental organism.
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Introduction
Planarians are one of the best-characterized animal models in 
developmental biology and regeneration research (Newmark and 
Sánchez Alvarado, 2002) and are currently being rediscovered 
as a very useful animal model in neuropharmacology (Buttarelli et 
al., 2008; Raffa and Rawls, 2008). Planarians are the first extant 
example of organisms displaying cephalization, including a primitive 
brain, sometimes referred to as cerebral ganglia, with many features 
in common with vertebrate nervous systems, such as multipolar 
neurons and dendritic spines (Sarnat and Netsky, 1985). Addition-
ally, nearly every neurotransmitter found in mammals is present in 
planarians (Buttarelli et al., 2008; Ribeiro et al., 2005). One of the 
most interesting properties of this class of organisms is their remark-
able capacity for regeneration, including the complete regeneration 
of their cerebral ganglia upon decapitation (Cebrià, 2007; Cebrià 
et al., 2002; Gentile et al., 2011). Working with this organism has 
several practical advantages. They are commercially available at 
very low cost and are very easily kept in the laboratory. No special 
equipment such as incubators, etc., is necessary. Additionally, the 
genome of a planarian species (Schmidtea mediterranea) has 
been sequenced (Robb et al., 2008), which will undoubtedly help 
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to understand these organisms at the molecular level.
Two specific planarian behavioral endpoints have proven useful 
in pharmacological experiments: the observation of changes in 
motility (Raffa et al., 2001) and the induction of planaria seizure-like 
movements (pSLM; Rawls et al., 2011; Fig. 1A). Both responses 
are easily quantified and have been used to study the effect of a 
wide variety of psychoactive agents and abused drugs (Raffa and 
Rawls, 2008; Rawls, 2011).
Parthenolide (Fig. 1B) is the active component of the feverfew 
plant (T. parthenium), used to treat migraines. This compound 
has several known biochemical effects, including the inhibition of 
serotonin type II receptors (Weber et al., 1997) and the enhance-
ment of NF-kB transcription factor function (Kang et al., 2002). 
Also, parthenolide displays anti-inflammatory effects and inhibits 
Ikappa-B kinases (Kwok et al., 2001).
Parthenolide and related compounds have been shown (1) to 
prevent the expression of cocaine-induced behaviors in planarians, 
such as motility decrease and seizure-like hyperkinesias (Pagán 
194    O.R. Pagán et al.
Fig. 1.  Effect of parthenolide against cocaine and amphetamine. (A) Representative planarian 
seizure-like movement.  The white bar is 1 cm long.  (B) Parthenolide structure.  (C) Parthenolide 
does not induce significant pSLMs. Each bar is the average of 4 worms.  (D) Cocaine-induced 
pSLMs in the presence and in the absence of 50 mM parthenolide. (E) Amphetamine-induced 
pSLMs in the presence and in the absence of 50 mM  parthenolide. Each bar is the average of 
4-8 worms. The error bars represent the standard error of the mean. The number at the upper 
right corner of (D,E) represent the p-values generated by two-way ANOVA. The asterisks over 
some of the bars indicate significant difference between the column pairs (“*”< 0.05; “**” 
< 0.01) via a Bonferroni post-test.
et al., 2008) and (2) to prevent the expression of withdrawal-like 
behaviors induced by cocaine (Rowlands and Pagán, 2008). The 
lactone moiety of the parthenolide molecule is essential for its 
cocaine-antagonist properties (Pagán et al., 2008). Further work 
established that the lactone moiety with a 4-methyl tail is suf-
ficient to prevent the motility decrease induced by cocaine (Baker 
et al., 2011). Significantly, similar results have been observed in 
vertebrates. Parthenolide alleviates the cocaine-induced effects 
on spontaneous firing of dopaminergic neurons in the ventral 
tegmental area of rats (Schwarz et al., 2011).
Here we report that parthenolide prevents the pSLMs induced 
by cocaine but not the hyperkinesia induced by amphetamines, 
the cholinergic ligands nicotine and cytisine, or the glutamatergic 
ligands L- of D-glutamic acid and NMDA. These results suggest 
that parthenolide is a specific behavioral antagonist for cocaine in 
our experimental conditions.
Results
Fig. 1C shows that parthenolide up to a concentration of 50 mM 
does not induce significant pSLMs. This is consistent with previous 
reports, which show that at this concentration, parthenolide does not 
seem to produce any behavioral effects on the planarians (Pagán 
et al., 2008; Rowlands and Pagán, 2008). Based on this, we used 
parthenolide at a concentration of 50 mM in all subsequent experi-
ments. Fig. 1D shows that that 50 mM parthenolide prevents the 
reuptake to the presynaptic terminal, hence 
regulating neurotransmission (Zahniser and 
Doolen, 2001). Neurotransmitter reuptake by 
specialized transporters was proposed as an 
inactivation mechanism as early as 50 years 
ago using radiolabeled noradrenaline (Hertting 
and Axelrod, 1961). The effect of cocaine in 
noradrenaline reuptake was also demonstrated 
using the same technique (Hertting et al., 1961). 
Since then, this inactivation mechanism has 
been demonstrated in many neurotransmitter 
systems (Torres et al., 2003). When abused 
drugs such as cocaine and amphetamine inter-
act with the DAT, the dopamine concentration 
increases in the synaptic cleft; this increase 
causes a direct hyperactivation of postsynaptic 
dopamine receptors as well as extrasynaptic 
dopamine autoreceptors (Callier et al., 2003). 
In fact, one of the main roles of the DAT seems 
to be the regulation of dopamine spillover to 
these autoreceptors (Cragg and Rice, 2004). 
In humans, the main target for cocaine and 
amphetamine is the DAT (Uhl et al., 2002). 
Interestingly, DAT-knockout rodents are still 
sensitive to cocaine through increased participa-
tion of the NET and SERT in this process (Hall 
et al., 2004).
In light of this information, our results show-
ing that parthenolide prevented the behavioral 
effects of cocaine but not amphetamine was 
unexpected, since cocaine and amphetamines 
both interact with neurotransmitter transporters, 
albeit through different mechanisms. Cocaine 
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induction of cocaine-induced pSLM, as described before (Pagán 
et al., 2008). Interestingly, parthenolide did not alleviate the be-
havioral response induced by amphetamines (Fig. 1E). However, 
please note that even though the global ANOVA p-values does 
not indicate a statistical difference between the worms exposed 
to amphetamine and the worms exposed to amphetamine/parthe-
nolide in the whole curves, parthenolide significantly reduces the 
incidence of pSLM at the highest amphetamine concentration (10 
mM). Also, parthenolide did not prevent the expression of pSLM 
in response to the cholinergic agents nicotine and cytisine (Fig. 
2 A,B) or the glutamatergic ligands L- glutamic acid, D-glutamic 
acid or NMDA (Fig. 2 C,D,E). 
Discussion
The negative results of parthenolide against all tested com-
pounds except cocaine indicate a very important property of 
parthenolide, specificity. In clinical pharmacology, one of the main 
problems associated with medications are side effects, which are 
brought about by the interaction of a particular drug with multiple 
targets (Sheridan, 2003).
The accepted target for cocaine and amphetamines is the 
monoamine transporter (MAT) superfamily, which includes the 
dopamine transporter (DAT), the serotonin transporter (SERT) 
and the norepinephrine transporter (NET) (Torres et al., 2003). 
The main function of the MATs is to regulate neurotransmitter 
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is a reuptake blocker, preventing the transport of the neurotrans-
mitter back to the presynaptic site; amphetamine is considered 
a “releaser”, which acts as a false substrate of the transporter 
(Riddle et al., 2005). In both cases, the net result is the abnormal 
increase of neurotransmitter molecules in the synaptic cleft, which 
accounts for the drug’s psychoactive properties (Iversen, 2006; 
Sager and Torres, 2011).
Using vertebrate pharmacology as a point of reference, our 
results suggests that parthenolide prevents the pSLM induced by 
cocaine by inhibiting an interaction with dopaminergic systems. 
However, this is not consistent with the amphetamine results 
(Fig. 1E) or by the fact that no significant pSLMs are detected 
when exposing the worms to a dopamine concentration of 1 mM 
(data not shown). Interestingly, preliminary results with another 
planarian species, Dugesia dorotocephala, seem to indicate that 
parthenolide alleviates amphetamine-induced pSLM (Rawls et 
al., unpublished data). A possible interpretation is that in planar-
ians, any catecholamine responses are modulated by compounds 
such as norepinephrine, octopamine or tyramine, as opposed to 
dopamine. Another implication of our results is that the pSLM are 
induced by cocaine/amphetamines and by cholinergic/glutama-
tergic compounds by interacting with different protein targets. 
This is amenable to pharmacological dissection of these distinct 
mechanisms.
In future experiments, we will study the effect of parthenolide 
against cocaine and amphetamine-like compounds in planarian 
behavior using paradigms such as conditioned place preference 
(Rawls et al., 2011), cross-sensitization (Rawls et al., 2010) and 
withdrawal-like behavior (Sacavage et al., 2008).
In a broader context, this work highlights the usefulness 
of planarians as an important animal model in pharmacology. 
In addition to the multiple advantages of using planarians 
described above, this model has been demonstrated to be 
relevant to mammalian pharmacology (Schwarz, 2011). 
Furthermore, since they can be studied all the way from 
molecular biology to behavior, these organisms will likely 
be developed as important tools in drug discovery research.
Materials and Methods
Girardia tigrina were purchased from Ward’s (Rochester, NY). 
The tested compounds were obtained from Sigma-Aldrich (St. Louis, 
MO) or Tocris (Ellisville, MO). General laboratory materials were 
purchased from Fisher Scientific (Suwanee, GA). All graphs and 
statistical procedures were done using the Prism software package 
(GraphPad Inc., La Jolla, CA). The experiments were carried out at 
room temperature using artificial pond water (APW, NaCl, 6 mM; 
NaHCO3, 0.1 mM; CaCl2, 0.6 mM). Dimethylsulfoxide (DMSO) at 
a concentration of 0.1% was present in all experimental solutions 
as a solubility-aiding agent for parthenolide. At this concentration, 
DMSO does not induce any observable behavioral or toxic effects 
in planarians (Pagán et al., 2006).
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